Is this congestive heart failure when the echocardiogram shows moderately decreased left ventricular systolic function with a left ventricular ejection fraction of 35–40%?

Is an LVEF of 35-40% Congestive Heart Failure?

Yes, an echocardiogram showing moderately decreased left ventricular systolic function with LVEF 35-40% meets the diagnostic criteria for heart failure with reduced ejection fraction (HFrEF), provided the patient has typical symptoms or signs of heart failure. 1

Diagnostic Criteria for HFrEF

To establish the diagnosis of HFrEF, three conditions must be satisfied 1:

• Symptoms typical of heart failure (dyspnea, fatigue, exertional limitation) 1, 2
• Signs typical of heart failure (elevated jugular venous pressure, pulmonary crackles, peripheral edema, though these may be absent early or in diuretic-treated patients) 1
• Reduced LVEF ≤40% 1

Your patient's LVEF of 35-40% falls squarely within the HFrEF definition used by both ACC/AHA and ESC guidelines, which define HFrEF as LVEF ≤40%. 1, 3

Critical Clinical Context

The term "congestive heart failure" specifically refers to heart failure with evidence of volume overload (sodium and water retention), and congestion may resolve with diuretic treatment even though the underlying systolic dysfunction persists 1. Not all patients with HFrEF present with congestion—some may have fatigue or exertional limitation as their primary symptom. 1

Importantly, patients with LVEF in the 35-40% range may be asymptomatic or minimally symptomatic, particularly early in the disease course. 1, 3 These patients are described as having "asymptomatic LV systolic dysfunction" if they have never exhibited typical symptoms, but they still require aggressive disease-modifying therapy 1.

Immediate Management Priorities

Foundational Pharmacotherapy

All patients with LVEF ≤40% should receive quadruple therapy unless contraindicated 3, 4, 5:

• ACE inhibitors or ARBs (with angiotensin receptor-neprilysin inhibitors [ARNI] preferred over ACE inhibitors) should be initiated and titrated to target doses 3, 4
• Evidence-based beta-blockers (bisoprolol, metoprolol succinate, carvedilol, or nebivolol only—not other beta-blockers) 1, 6
• Mineralocorticoid receptor antagonists (spironolactone or eplerenone) for patients who remain symptomatic despite first-line therapy 1
• SGLT2 inhibitors (dapagliflozin or empagliflozin) are now recommended in all patients with HFrEF regardless of diabetes status 4, 7

Device Therapy Evaluation

LVEF 35-40% sits at the critical threshold for device therapy eligibility established in major randomized trials 3:

• ICD for primary prevention should be evaluated in patients with LVEF ≤35% who have coronary artery disease or other structural heart disease, as this threshold was the inclusion criterion in trials demonstrating mortality benefit 1, 3
• Cardiac resynchronization therapy (CRT) should be considered if QRS duration is ≥120 ms, particularly if ≥150 ms or if mechanical dyssynchrony is present on echocardiography 1
• The benefit of ICD implantation increases as ejection fraction decreases below 35%, with patients having LVEF <30% showing larger mortality reductions (HR 0.72) compared to those with LVEF 30-35% (HR 0.83) 3

Critical Pitfalls to Avoid

Do not rely on a single LVEF measurement for long-term risk stratification. 8, 9 Recent evidence demonstrates that LVEF category changes significantly over time—in one study, 45% of patients with initial LVEF ≤35% improved to >35% at final assessment before sudden cardiac death, and 41% of all patients were reclassified based on LVEF changes 9. Serial echocardiographic assessments are necessary to track trajectory and adjust therapy accordingly. 8

Do not delay device therapy evaluation while attempting to optimize medical therapy alone—these interventions should proceed in parallel for eligible patients. 3 The high-intensity care strategy with rapid up-titration of guideline-directed medical therapy after diagnosis has been associated with better outcomes 7.

Avoid nondihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with LVEF ≤40%, as they have negative inotropic effects and may worsen outcomes 3.

Do not assume patients with LVEF 35-40% are "borderline" or low-risk. 3 This LVEF range represents validated high-risk thresholds based on robust trial data, and these patients have substantial morbidity and mortality risk requiring aggressive intervention 3, 2.

Prognosis and Risk Stratification

Patients with LVEF 35-40% have a more favorable prognosis than those with more severe systolic dysfunction (LVEF <35%), with lower cumulative mortality and less frequent heart failure hospitalizations. 10 However, the 5-year survival rate after hospitalization for HFrEF remains only 25%, underscoring the need for comprehensive disease-modifying therapy. 2

Elevated natriuretic peptides (BNP >35 pg/mL or NT-proBNP >125 pg/mL) provide additional diagnostic specificity and prognostic information. 1 Serial monitoring of natriuretic peptides should be considered in patients where up-titration of pharmacologic therapy is problematic or in those with a history of hospitalization for heart failure exacerbations 1.